SEARCH

SEARCH BY CITATION

References

  • ADELL, A. & ARTIGAS, L. (1991). Differential effects of clomipra-mine given locally or systemically on extracellular 5-hydroxy-tryptamine in raphe nuclei and frontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 237244.
  • AGHAJANIAN, G.K. (1995). Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In Psychopharma-cology: the Fourth Generation of Progress, ed. BLOOM, F.E. & KUPFER, DJ. pp. 451460. New York: Raven Press.
  • AGHAJANIAN, G.K., WANG, R.Y. & BARABAN, L (1978). Seroto-nergic and non-seretonergic neurons of the dorsal raphe: reciprocal changes in firing induced by peripheral nerve stimulation. Brain Res., 153, 169175.
  • ARBORELIUS, L., NOMIKOS, G.G., GRILLNER, P., HERLEL, P., BACKLUND, HÖÖK B., HACKSELL, U. & SVENSSON, L.H. (1995). 5JJT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol., 352, 157165.
  • ASHBY, C.R. & WANG, R.Y. (1996). Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse, 24, 349394.
  • ASSIE, M.-B. & KOEK, W. (1996). Effects of 5JJT1A receptor antagonists on hippocampal 54iydroxytryptamine levels: (S)-WAY100135, but not Way100635, has partial agonist properties. Eur. J. Pharmacol, 304, 1521.
  • AXELSSON, R., NILSSON, A., CHRISLENSSON, E. & BJÖRK, A. (1991). Effects of amperozide in schizophrenia. Psychopharma-cology, 104, 287292.
  • BARABAN, J.M. & AGHAJANIAN, G.K. (1980). Suppression of firing activity of 5JJT neurons in the dorsal raphe by alpha-adrenoceptor antagonist. Neuropharmacology, 19, 355363.
  • BJÖRK, A., BERGMAN, I. & GUSLAVSSON, G. (1992). Amperozide in treatment of schizophrenic patients. A preliminary report. In Novel Antipsychotic Drugs, ed. MELTZER, H.Y. pp. 4757. New York: Raven.
  • BLIER, P., DE MONLIGNY, C, & CHAPUL, Y. (1987). Modifications of the serotonin system by antidepressant treatment: Implications for the therapeutic response in major depression. J. Clin. PsychopharmacoL, 7, S24S35.
  • BORISON, R.L., PALHIRAJA, P.A., DIAMOND, B.I. & MEIBACH, R.C. (1992). Risperidone: clinical safety and efficacy in schizophrenia. PsychopharmacoL Bull., 28, 213218.
  • CARBONI, E. & DI CHIARA, G. (1989). Serotonin release estimated by transcortical dialysis in freely moving animals. Neuroscience, 32, 637645.
  • CHAPUL, Y., LESIEUR, P. & DE MONLIGNY, C. (1990). Effects of short-term serotonin depletion on the efficacy of serotonin neurotransmission: Electrophysiological studies in the rat central nervous system. Synapse, 6, 328337.
  • CHOUINARD, G., JONES, B., REMINGLON, G., BLOOM, D., AD-DINGLON, D., MACEWAN, G.W., LABELLE, A., BEAUCLAIR, L. & ARNOLL, W. (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. PsychopharmacoL, 13, 2540.
  • CUNNINGHAM, K.A. & LAKOSKI, J.M. (1990). The interaction of cocaine with serotonin dorsal raphe neurons: single-unit extracellular recording studies. Neuropsychopharmacology, 3, 4150.
  • DAVIDSON, C. & SLAMFORD, LA. (1995). Evidence that 5-hydroxytryptamine release in the rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br. J. Pharmacol., 114, 11071109.
  • DAVIS, J.M. & JANICAK, P.G. (1996). Risperidone: A new, novel (and better?) antipsychotic. Psychiat. Ann., 26, 7887.
  • FREEDMAN, J.E. & AGHAJANIAN, G.K. (1984). Idazoxan (RX 781094) selectively antagonizes a2-adrenoceptors on rat central neurons. Eur. J. Pharmacol., 105, 265272.
  • GALLAGER, D.W. & AGHAJANIAN, G.K. (1975). Effects of chloripramine and lysergic acid diethylamide on efflux of precursor-formed 3H-serotonin: Correlations with serotonergic impulse flow. J. Pharmacol. Exp. Ther., 193, 785795.
  • GALLAGER, D.W. & AGHAJANIAN, G.K. (1976). Effect of anti-psychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur. J. Pharmacol., 39, 341355.
  • GARRATT, J.C., CRESPI, F., MASON, R. & MARSDEN, C.A. (1991). Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur. J. Pharmacol., 193, 8793.
  • GARTSIDE, S.E., UMBERS, V. & SHARP, T. (1997). Inhibition of 5-HT cell firing in the Drn by non-selective 5-HT reuptake inhibitors: Studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms. Psychopharmacology, 130, 261268.
  • GOFF, D.C., MIDHA, K.K., SARID-SEGAL, O., HUBBARD, J.W. & AMICO, E. (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology, 117, 417423.
  • GOLDMAN, M.B. & JANECEK, H.M. (1990). Adjunctive fluoxetine improves global function in chronic schizophrenia. J. Neuropsy-chiatr., 2, 429431.
  • HAJOS, M., GARTSIDE, S.E. & SHARP, T. (1995). Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn-Schmiedeberg's Arch. Pharmacol., 351, 624629.
  • HERTEL, P., NOMIKOS, G.G., IURLO, M. & SVENSSON, T.H. (1996). Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology, 124, 7486.
  • HERTEL, P., NOMIKOS, G.G., SCHILSTRÖM, B., ARBORELIUS, L. & SVENSSON, T.H. (1997). Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of a2 adrenoceptor antagonism. Neuropsychopharmacology, 17, 4455.
  • HJORTH, S., BENGTSSON, H.J., MILANO, S., LUNDBERG, J.F. & SHARP, T. (1995). Studies on the role of 5-HT1A autoreceptors and ai-adrenoceptors in the inhibition of 5-HT release-1. Bmy7378 and prazosin. Neuropharmacology, 34, 615620.
  • HOFFMAN, B.B. & LEFKOWITZ, R.J. (1990). Adrenergic receptor antagonists. In Goodman and Gilmans The Pharmacological Basis of Therapeutics, ed. OILMAN, A.G., RAIL, T.W., NIES, A.S. & TAYLOR, P. 8th Ed. pp. 221243. New York: Pergamon Press.
  • INVERNIZZI, R., BELLI, S. & SAMANI, R. (1992). Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe nuclei prevents the drug's effect in the frontal cortex. Brain Res., 584, 322324.
  • JACOBS, B.L. & AZMITIA, E.C. (1992). Structure and function of the brain serotonin system. Physiol. Rev., 72, 165229.
  • KANE, J., HONIGFELD, G., SINGER, J. & MELTZER, H.Y. (1988). Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry, 45, 789796.
  • KOE, B.K. & WEISSMAN, A. (1966). β-Chlorophenylalanine: A specific depletor of brain serotonin. J. Pharmacol. Exp. Ther., 154, 499516.
  • KÖHLER, C, HALL, H., ÖGREN, S.-O. & GAWELL, L. (1985). Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the brain. Biochem. Pharmacol., 34, 22512259.
  • LEJEUNE, F., AUDINOT, V., GOBERT, A., RIVET, J.M., SPEDDING, M. & MILLAN, M.J. (1994). Clozapine inhibits serotonergic transmission by an action at aradrenoceptors not at 5-HT1A receptors. Eur. J. Pharmacol., 260, 7983.
  • LEYSEN, J.E., GOMMEREN, W., EENS, A., DE CHAFFOY DE COURCELLES D., STOOF, J.C. & JANSSEN, P.A.J. (1988). Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther., 247, 661670.
  • LEYSEN, J.E., JANSSEN, P.F.M., GOMMEREN, W., WYNANTS, J., PAUWELS, P.J. & JANSSEN, P.A.J. (1992). In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol. Pharmacol., 41, 494508.
  • LITMAN, R.E., SU, T.P., POTTER, W.Z., HONG, W.W. & PICKAR, D. (1996). Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br. J. Psychiatry, 168, 571579.
  • MATOS, F.F., URBAN, C. & YOCCA, F.D. (1996). Serotonin (5-HT) release in the dorsal raph6 and ventral hippocampus: raph6 control of somatodendritic and terminal 5-HT release. J. Neural. Transm., 103, 173190.
  • MATSUBARA, S., MATSUBARA, R., KUSUMI, I., KOYAMA, T. & YAMASHITA, I. (1993). Dopamine D1; D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J. Pharmacol. Exp. Ther., 265, 498508.
  • MAURA, G., BONANNO, G. & RAITERI, M. (1992). Presynaptic a2-adrenoceptors mediating inhibition of noradrenaline and 5-hydroxytryptamine release in rat cerebral cortex: further characterization of different a2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 410416.
  • MESOTTEN, F., SUY, E., PIETQUIN, M., BURTON, P. & HEYLEN, S. (1989). Therapeutic effect and safety of increasing dose of risperidone (R64744) in psychotic patients. Psychopharmacology, 99, 445449.
  • PALFREYMAN, M.G., SCHMIDT, C.J., SORENSEN, S.M., DUDLEY, M.W., KEHNE, J.H., MOSER, P., GITTOS, M.W. & CARR, A.A. (1993). Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology, 112, 6067.
  • PAXINOS, G. & WATSON, C. (1986). The Rat Brain in Stereotaxic Coordinates. 2nd Ed. Syndey: Academic Press.
  • PINEYRO, G., DE MONTIGNY, C, WEISS, M. & BLIER, P. (1996). Autoregulatory properties of dorsal raphe-5HT neurons: possible role of electrotonic coupling and 5-HTiD receptors in the rat brain. Synapse, 22, 5462.
  • SCHOTTE, A., JANSSEN, P.F.M., GOMMEREN, W., LUYTEN, W.H.M.L., VAN COMPEL, P., LESAGE, A.S., DE LOORE, K. & LEYSEN, J.E. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 124, 5773.
  • SILVER, H. & NASSAR, A. (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry, 31, 698704.
  • SPINA, E., DE DOMENICO, P., RUELLO, C, LONGOBARDO, N., GITTO, C, ANCIONE, M., DI ROSA, A.E. & CAPUTI, A.P. (1994). Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol., 9, 281285.
  • STARKE, K., GÖTHERT, M. & KILBINGER, H. (1989). Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev., 69, 864989.
  • SUMIYOSHI, T., KIDO, H., SAKAMOTO, H., URASAKI, K., SUZUKI, K., YAMAGUCHI, N., MORI, H., SHIBA, K. & YOKOGAWA, K. (1994). In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav., 47, 553557.
  • SVARTENGREN, J. & SIMONSSON, P. (1990). Receptor binding properties of amperozide. Pharmacol. Toxicol., 66, 811.
  • SVENSSON, T.H., BUNNEY, B.S. & AGHAJANIAN, G.K. (1975). Inhibition of both noradrenergic and serotonergic neurons in brain by the a-adrenergic agonist clonidine. Brain Res., 92, 291306.
  • VANDERMAELEN, C.P. & AGHAJANIAN, G.K. (1983). Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellulary in rat brain slices. Brain Res., 289, 109119.
  • WANG, RY. & AGHAJANIAN, G. (1978). Collateral inhibition of serotonergic neurones in the rat dorsal raphe nucleus: Pharmacological evidence. Neuropharmacology, 17, 819825.